Skip to main content
ARS Home » Research » Publications at this Location » Publication #216268
Title: Swine Toolkit Progress for US Veterinary Immune Reagent Network

Author
item Lunney, Joan
item Boyd, Patricia
item Zarlenga, Dante
item ZUCKERMANN, FEDERICO - U ILLINOIS, URBANA
item SCHNITZLIEN, WILLIAM - U ILLINOIS, URBANA
item LABRESH, JOANNA - ST PAUL, MN
item WAGNER, BETTINA - CORNELL U, ITHACA NY
item BALDWIN, CYNTHIA - U MASS AMHERST

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 10/27/2007
Publication Date: 12/2/2007
Citation: Lunney, J.K., Boyd, P., Zarlenga, D.S., Zuckermann, F., Schnitzlien, W., Labresh, J., Wagner, B., Baldwin, C. December 2007. Swine Toolkit Progress for US Veterinary Immune Reagent Network. In: R. Elis Ed., Proceedings of the Conference of Research Workers in Animal Diseases (CRWAD) Meeting, Blackwell Publishing. p.107 #80P.

Interpretive Summary:

Technical Abstract: The US Veterinary Immune Reagent Network (http://www.umass.edu/vetimm/) was established to address the lack of immunological reagents for veterinary species. Within this context, plans are underway to produce sets of reagents needed to evaluate immune changes during disease and following vaccination. These reagents include: recombinant cytokines and chemokines; monoclonal antibodies (mAb) that recognize them and their receptors; and mAb that identify the major leukocyte subsets, CD antigens, T cell receptor (TCR) and Toll-like receptors (TLR) with a goal of 20 reagents per species group. For the US Swine Toolkit, we first assembled an inventory of available swine reagents from which we could prioritize and launch the development of a new materials based on the following criteria: 1) importance for swine immunity studies; 2) priority relative to other toolkit efforts; 3) availability of swine immune gene transcript sequence information; and 4) likelihood of successful development of the reagent. Since many swine cytokine and CD reagents are accessible, we have focused on generating anti-TCR''''mAb, bioactive chemokines and mAb to them and their receptors. Efforts are also underway to produce bioactive interferon (IFN)-', interleukin (IL)-7, IL-15 and IL-13 and relevant mAb. Because anti-CD45RO mAb could not be produced using traditional methods, a peptide immunization protocol has been initiated. Given the sequence similarity among the broad group of TLR, cross reactivity of known human anti-TLRs mAb reagents is being evaluated before advancing this effort de novo within the envelope of the swine toolkit. Products developed by the US Veterinary Immune Reagent Network will be openly available to collaborators and be made commercially available using non-exclusive licenses. We expect our efforts to benefit a large group of researchers including veterinary immunologists, pathologists, microbiologists and scientists using swine as a biomedical model for humans. This project was funded by USDA NRICGP and ARS.